Iterum Therapeutics sees cash runway into 2H25

Cash and cash equivalents were $24.1M as of December 31, 2024. Based on Iterum’s current operating plan, Iterum expects that its cash and cash equivalents, including $4.8M of net proceeds raised under its at-the-market offering program from January 1, 2025 through February 6, 2025, will be sufficient to fund its operations into the second half of 2025. The foregoing estimate gives effect to the repayment of the Exchangeable Notes in January 2025 and includes Iterum’s currently planned pre-commercialization activities. As of February 6, 2025, Iterum had approximately 34.6M ordinary shares outstanding.